Effects and mechanisms of PSS-loaded nanoparticles on coronary microcirculation dysfunction in streptozotocin-induced diabetic cardiomyopathy rats

• Published in: Biomedicine & pharmacotherapy 2020-01, Vol.121, p.109280-109280, Article 109280
• Main Authors: Mao, Yongjun, Hu, Yi, Feng, Wenjing, Yu, Luyan, Li, Pengli, Cai, Bing, Li, Chunxia, Guan, Huashi
• Format: Article
• Language: English
• Subjects: Coagulation; Diabetic cardiomyopathy; Microcirculation dysfunction; Oxidative stress; PSS-loaded nanoparticles; Vascular endothelial function
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2019.109280

•PSS-NP can improve the cardiac structural disorder and the cardiac function.•PSS-NP can increase the number of microvessels and enhance their activity.•PSS-NP can improve endothelial function and reduce microcirculation dysfunction.•PSS-NP can improve the microcirculation dysfunction by anticoagulation.•PSS-NP can reduce microcirculation dysfunction through antioxidant stress. Coronary microvascular dysfunction (CMD) is the pathological basis and pathogenesis of diabetic cardiomyopathy (DCM). Propylene glycol alginate sodium sulfate (PSS) as heparinoid drug has many biological activities. Here, a novel PSS-loaded nanoparticle (PSS-NP) was prepared to study its effect on the CMD of DCM. We used diabetes mellitus rat induced by STZ to establish the CMD model of DCM, and the study was detected by echocardiography, histological analysis, transmission electron microscopy, immunofluorescence staining, enzyme-linked immunosorbent assay, real time-PCR analysis, liquid-chip analysis, western blot analysis and so on. The experimental results suggested that PSS-NP could improve the survival state of rats, cardiac function, myocardial morphology and coronary microcirculation structure disorders, and increase the number of microvessels. In addition, we demonstrated that PSS-NP could alleviate the CMD by improving endothelial function, anticoagulation and antioxidative stress. The outcomes of this study provided new treatment thoughts for the therapy of coronary microcirculation dysfunction in DCM.